ANAB stock forecast, quote, news & analysis
AnaptysBio Inc is a clinical-stage biotechnology company... Show more
Why AnaptysBio (ANAB) Stock Is Down -18% in the Last 30 Days
Key Takeaways
- ANAB has declined roughly 18% over the last 30 days, sliding from about $55.20 to the mid-$40s.
- The pullback follows a strong first-half run, with shares still up more than 50% year-to-date.
- An unresolved Delaware dispute over the Jemperli royalty collaboration with GSK remains a central overhang.
- FDA accelerated approval of Jemperli for a rectal cancer indication briefly lifted shares in mid-October.
- Analyst consensus remains a "Strong Buy" with an average target near $87, though several firms trimmed targets in September.
AnaptysBio (ANAB) Company Overview and Market Position
AnaptysBio is now a pure-play royalty-management company. In April 2026, the company completed the spin-off of its biopharma operations into First Tracks Biotherapeutics (TRAX), which took the clinical-stage pipeline. Today, AnaptysBio exclusively manages the financial collaborations for two out-licensed assets: Jemperli (dostarlimab), a PD-1 antagonist licensed to GlaxoSmithKline (GSK), and imsidolimab, an IL-36R antagonist licensed to Vanda Pharmaceuticals (VNDA).
The company operates a lean, virtual business model targeting a greater than 95% EBIT margin, with a focus on protecting and returning royalty value to shareholders. Investors follow ANAB for its royalty cash-flow profile and for litigation-driven optionality tied to the Jemperli agreement.
AnaptysBio (ANAB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ANAB has fallen roughly 18%. The shares closed near $55.20 in mid-September and have since declined to the mid-$40s, with the latest available price around $45.28. The move has been uneven, including a brief rally following regulatory news in mid-October before renewed selling.
The broader quarterly trend is also negative. Over the trailing three months, ANAB is down roughly 30%, retreating from a mid-July peak above $69 to the current level. Despite this correction, the stock has preserved the large majority of its gains from earlier in the year, reflecting a pullback within a still-elevated longer-term uptrend.
What Drove ANAB Stock Price in the Last 30 Days
The dominant factor has been uncertainty surrounding the company's Delaware litigation over the Jemperli collaboration with GSK's Tesaro unit. The dispute centers on whether Tesaro fulfilled its contractual obligations in prioritizing Jemperli, and oral arguments with an expected ruling in late 2026 or early 2027 remain a key swing factor for the royalty stream.
Analyst activity also weighed on sentiment. In late September, several firms lowered price targets: J.P. Morgan trimmed its target from $70 to $60, Leerink Partners from $90 to $81, while Barclays and UBS maintained Buy ratings with targets of $75 and $76, respectively. Separately, H.C. Wainwright reiterated a Buy rating with a $95 target, citing potential litigation upside.
On the fundamental side, AnaptysBio reported quarterly results in early October that exceeded consensus estimates, including revenue of $27.49 million versus a $14.06 million expectation. The beat, however, did not halt the decline. In mid-October, the FDA granted accelerated approval to Jemperli for stage II and III MSI-high/dMMR locally advanced rectal cancer, lifting shares more than 5% in a single session before the gains faded amid broader profit-taking.
What Drove ANAB Stock Performance Over the Last Quarter
The quarterly decline reflects a transition in how the market values the post-spin-off company. After the April separation of First Tracks Biotherapeutics, ANAB re-rated as a royalty entity, and the stock climbed sharply through the first half of the year before peaking in mid-July. Since then, the shares have corrected as investors reassess the litigation risk, the trajectory of Jemperli royalty growth, and the pace of analyst price-target reductions.
Broader sentiment in the biotechnology and specialty-pharmaceutical sector has also contributed to the drawdown. With limited operational costs and royalty-heavy economics, ANAB's near-term value is heavily concentrated in the resolution of the GSK dispute and the commercial performance of Jemperli, making the shares sensitive to any shift in the legal or regulatory narrative.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies designed to identify opportunities across the market. Tickeron offers hundreds of AI-powered trading bots that trade thousands of tickers, but only the top-performing and most relevant robots appear in this section. Each bot differs in strategy, holding timeframe, and performance metrics, allowing traders to match a system to their own objectives and risk tolerance. The page serves as a resource for investors evaluating data-driven approaches to position management and market timing. Explore the Trending AI Robots page to review current strategies and performance.
ANAB Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the Delaware litigation timeline closely, as oral arguments and a ruling expected in late 2026 or early 2027 could materially affect the Jemperli royalty economics. A second near-term catalyst is the FDA decision on Vanda's imsidolimab for generalized pustular psoriasis, which carries a target action date of December 12, 2026 and would add a second commercial royalty asset.
Beyond these events, GSK's Jemperli sales growth, quarterly royalty revenue reports, and any further analyst rating or price-target revisions will shape sentiment. Macroeconomic conditions and sector-wide risk appetite in biotechnology remain additional variables. These factors represent potential drivers to watch, not financial guidance, and each carries meaningful uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANAB's RSI Oscillator recovers from oversold territory
The RSI Indicator for ANAB moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 19 of the 21 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ANAB as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.
Following a +6.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 226 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ANAB entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ANAB's P/B Ratio (112.433) is very high in comparison to the industry average of (2.988). P/E Ratio (-47.000) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of therapeutic antibodies for inflammation and immuno-oncology
Industry Biotechnology